High-dose of intravenous methylprednisolone versus oral in treatment of acute asthmatic patients: a cohort study


doi: 10.18081/2333-5106/015-06/345-353
American Journal of BioMedicine Volume 3, Issue 6, pages 345-353
Published: June 25, 2015

Borchers Sichuan, Quan-Ming Zhou, Chao Gay, Zeng Wong, Guo Goh


Asthma management depended on the severity of the disease, which is determined according to patient lung function [forced expiratory volume in 1 second (FEV1)], daytime and nocturnal symptoms, and the frequency of rescue bronchodilator use. A longitudinal analysis of each cluster in a China adult asthma cohort was performed to investigate the clinical significance of used high-dose of intravenous methylprednisolone versus oral in treatment of acute asthmatic patients. Oral administration of high-dose methylprednisolone was not inferior to intravenous administration for improvement of acute sthmatic patient and had a similar safety profile. This finding could have implications for access to treatment, patient comfort, and cost, but indication should always be properly considered by clinicians.

Keywords: Asthma; Methylprednisolone; Oral treatment; FEV1

Limited Access           Full Text-PDF                Feedback


1. Bateman ED, Hurd SS, Barnes PJ, et al. Global strategy for asthma management and prevention. GINA executive summary. Eur Respir J 2008; 31:143–178. [PubMed]

2. Miller MK, Johnson C, Miller DP, et al. Severity assessment in asthma: An evolving concept. J Allergy Clin Immunol 2005; 116:990–995. [PubMed]

3. Haldar P, Pavord ID, Shaw DE, et al. Cluster analysis and clinical asthma phenotypes. Am J Respir Crit Care Med 2008; 178:218–224. [PubMed]

4. Green RH, Brightling CE, Bradding P. The reclassification of asthma based on subphenotypes. Curr Opin Allergy Clin Immunol  2007; 7:43–50. [PubMed]

5. Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113: 59–65. [PubMed]

6. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982; 38:963–974. [PubMed]

7. Cnaan A, Laird NM, Slasor P. Using the general linear mixed model to analyse unbalanced repeated measures and longitudinal data. Stat Med 1997;16:2349–2380. [PubMed]

8. Sellebjerg F, Frederiksen JL, Nielsen PM, Olesen J. Double-blind, randomized, placebo-controlled study of oral, high-dose methylprednisolone in attacks of MS. Neurology 1998; 51:529–534. [PubMed]

9. Centers for Disease Control and Surveillance. Surveillance for asthma–United States, 1960–1995. MMWR Morb Mortal Wkly 1998; Rep 47(SS-1):1–28. [PubMed]

10. Aligne C, Auinger P, Byrd R, Weitzman M. Risk factors for pediatric asthma. Contributions of poverty, race, and urban residence. Am J Respir Crit Care Med 2000; 162:873–7. [PubMed]

11. McDaniel M, Paxson C, Waldfogel J. Racial disparities in childhood asthma in the United States: evidence from the National Health Interview Survey, 1997 to 2003. Pediatrics 2006; 117:868–77. [PubMed]

12. Salmond C, Crampton P, Hales S, Lewis S, Pearce N. Asthma prevalence and deprivation: a small area analysis. J Epidemiol Community Health 1999; 53:476–80. [PubMed]

13. Wright R, Mitchell H, Visness C, et al. Community violence and asthma morbidity: the Innercity Asthma Study. Am J Public Health 2004; 94:625–32. [PubMed]

14. Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med 2011; 364:2006–15. [PubMed]

15. Bergeron C, Al-Ramli W, Hamid Q. Remodeling in asthma. Proc Am Thorac Soc 2009;6:301–5. [PubMed]

16. Khetsuriani N, Kazerouni NN, Erdman DD, et al. Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol 2007;119:314–21. [PubMed]

17. Brar T, Nagaraj S, Mohapatra S. Microbes and asthma: The missing cellular and molecular links. Curr Opin Pulm Med 2012; 18:14–22. [PubMed]

18. Pollack CV, Jr, Pollack ES, Baren JM, et al. A prospective multicenter study of patient factors associated with hospital admission from the emergency department among children with acute asthma. Arch Pediatr Adolesc Med 2002;156:934–40. [PubMed]

19. Kelly HW. Levalbuterol for asthma: A better treatment? Curr Allergy Asthma Rep 2007;7:310–4. [PubMed]

20. Camargo CA, Jr, Gurner DM, Smithline HA, et al. A randomized placebo-controlled study of intravenous montelukast for the treatment of acute asthma. J Allergy Clin Immunol 2010;125:374–80. [PubMed]

21. Schuh S, Willan AR, Stephens D, Dick PT, Coates A. Can montelukast shorten prednisolone therapy in children with mild to moderate acute asthma. A randomized controlled trial? J Pediatr 2009;155:795–800. [PubMed]

22. Lin RY, Pesola GR, Bakalchuk L, et al. Rapid improvement of peak flow in asthmatic patients treated with parenteral methylprednisolone in the emergency department: A randomized controlled study. Ann Emerg Med 1999;33:487–94. [PubMed]

23. Rowe BH, Spooner C, Ducharme FM, Bretzlaff JA, Bota GW. Early emergency department treatment of acute asthma with systemic corticosteroids. Cochrane Database Syst Rev 2001:CD002178. [PubMed]

24. Manser R, Reid D, Abramson M. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev 2001:CD001740. [PubMed]

25. Ratto D, Alfaro C, Sipsey J, Glovsky MM, Sharma OP. Are intravenous corticosteroids required in status asthmaticus? JAMA 1988; 260:527–9. [PubMed]

26. Rodrigo GJ. Rapid effects of inhaled corticosteroids in acute asthma: An evidence-based evaluation. Chest 2006;130:1301–11. [PubMed]

Print Friendly, PDF & Email